Oragenics receives clearance to enroll patients in Belgium into its phase 2 trial of AG013
Oragenics announced it has received clearance to enroll patients residing in Belgium from the Belgian Health Authority, The Federal Agency for Medicines and Health Products, into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM. October 17, 2018